Literature DB >> 22864661

Identification of a novel NBN truncating mutation in a family with hereditary prostate cancer.

Kimberly A Zuhlke1, Anna M Johnson, Linda A Okoth, Elena M Stoffel, Christiane M Robbins, Waibov A Tembe, Claudia A Salinas, S Lilly Zheng, Jianfeng Xu, John D Carpten, Ethan M Lange, William B Isaacs, Kathleen A Cooney.   

Abstract

Nibrin (NBN), located on chromosome 8q21 is a gene involved in DNA double-strand break repair that has been implicated in the rare autosomal recessive chromosomal instability syndrome known as Nijmegen Breakage Syndrome (NBS). NBS is characterized by specific physical characteristics (microcephaly and dysmorphic facies), immunodeficiency, and increased risk of malignancy. Individuals who are heterozygous for NBN mutations are clinically asymptomatic, but may display an elevated risk for certain cancers including, but not limited to, ovarian and prostate cancer as well as various lymphoid malignancies. In this study, 94 unrelated familial prostate cancer cases from the University of Michigan Prostate Cancer Genetics Project (n = 54) and Johns Hopkins University (n = 40) were subjected to targeted next-generation sequencing of the exons, including UTRs, of NBN. One individual of European descent, diagnosed with prostate cancer at age 52, was identified to have a heterozygous 2117 C > G mutation in exon 14 of the gene, that results in a premature stop at codon 706 (S706X). Sequencing of germline DNA from additional male relatives showed partial co-segregation of the NBN S706X mutation with prostate cancer. This NBN mutation was not observed among 2768 unrelated European men (1859 with prostate cancer and 909 controls). NBN is involved in double-strand break repair as a component of the MRE11 (meiotic recombination 11)/RAD50/NBN genomic stability complex. The S706X mutation truncates the protein in a highly conserved region of NBN near the MRE11 binding site, thus suggesting a role for rare NBN mutations in prostate cancer susceptibility.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22864661      PMCID: PMC3485445          DOI: 10.1007/s10689-012-9555-1

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  30 in total

1.  Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search.

Authors:  J R Smith; D Freije; J D Carpten; H Grönberg; J Xu; S D Isaacs; M J Brownstein; G S Bova; H Guo; P Bujnovszky; D R Nusskern; J E Damber; A Bergh; M Emanuelsson; O P Kallioniemi; J Walker-Daniels; J E Bailey-Wilson; T H Beaty; D A Meyers; P C Walsh; F S Collins; J M Trent; W B Isaacs
Journal:  Science       Date:  1996-11-22       Impact factor: 47.728

2.  From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair.

Authors:  I Callebaut; J P Mornon
Journal:  FEBS Lett       Date:  1997-01-02       Impact factor: 4.124

3.  Distinct functional domains of nibrin mediate Mre11 binding, focus formation, and nuclear localization.

Authors:  A Desai-Mehta; K M Cerosaletti; P Concannon
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

4.  Mendelian inheritance of familial prostate cancer.

Authors:  B S Carter; T H Beaty; G D Steinberg; B Childs; P C Walsh
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

5.  Germline mutations in HOXB13 and prostate-cancer risk.

Authors:  Charles M Ewing; Anna M Ray; Ethan M Lange; Kimberly A Zuhlke; Christiane M Robbins; Waibhav D Tembe; Kathleen E Wiley; Sarah D Isaacs; Dorhyun Johng; Yunfei Wang; Chris Bizon; Guifang Yan; Marta Gielzak; Alan W Partin; Vijayalakshmi Shanmugam; Tyler Izatt; Shripad Sinari; David W Craig; S Lilly Zheng; Patrick C Walsh; James E Montie; Jianfeng Xu; John D Carpten; William B Isaacs; Kathleen A Cooney
Journal:  N Engl J Med       Date:  2012-01-12       Impact factor: 91.245

6.  ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway.

Authors:  D S Lim; S T Kim; B Xu; R S Maser; J Lin; J H Petrini; M B Kastan
Journal:  Nature       Date:  2000-04-06       Impact factor: 49.962

7.  An increased risk for malignant neoplasms in heterozygotes for a syndrome of microcephaly, normal intelligence, growth retardation, remarkable facies, immunodeficiency and chromosomal instability.

Authors:  E Seemanová
Journal:  Mutat Res       Date:  1990-05       Impact factor: 2.433

8.  NBS1 is a prostate cancer susceptibility gene.

Authors:  C Cybulski; B Górski; T Debniak; B Gliniewicz; M Mierzejewski; B Masojć; A Jakubowska; J Matyjasik; E Złowocka; A Sikorski; S A Narod; J Lubiński
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

9.  A new chromosomal instability disorder: the Nijmegen breakage syndrome.

Authors:  C M Weemaes; T W Hustinx; J M Scheres; P J van Munster; J A Bakkeren; R D Taalman
Journal:  Acta Paediatr Scand       Date:  1981-07

Review 10.  Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.

Authors:  Alexander Liede; Beth Y Karlan; Steven A Narod
Journal:  J Clin Oncol       Date:  2004-02-15       Impact factor: 44.544

View more
  5 in total

1.  A novel method for identifying disease associated protein complexes based on functional similarity protein complex networks.

Authors:  Duc-Hau Le
Journal:  Algorithms Mol Biol       Date:  2015-04-28       Impact factor: 1.405

2.  Disease-associated MRE11 mutants impact ATM/ATR DNA damage signaling by distinct mechanisms.

Authors:  Joshua A Regal; Todd A Festerling; Jeffrey M Buis; David O Ferguson
Journal:  Hum Mol Genet       Date:  2013-08-02       Impact factor: 6.150

3.  An inherited NBN mutation is associated with poor prognosis prostate cancer.

Authors:  C Cybulski; D Wokołorczyk; W Kluźniak; A Jakubowska; B Górski; J Gronwald; T Huzarski; A Kashyap; T Byrski; T Dębniak; A Gołąb; B Gliniewicz; A Sikorski; J Switała; T Borkowski; A Borkowski; A Antczak; L Wojnar; J Przybyła; M Sosnowski; B Małkiewicz; R Zdrojowy; P Sikorska-Radek; J Matych; J Wilkosz; W Różański; J Kiś; K Bar; P Bryniarski; A Paradysz; K Jersak; J Niemirowicz; P Słupski; P Jarzemski; M Skrzypczyk; J Dobruch; P Domagała; S A Narod; J Lubiński
Journal:  Br J Cancer       Date:  2012-11-13       Impact factor: 7.640

4.  A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer.

Authors:  Shona H Lang; Stephanie L Swift; Heath White; Kate Misso; Jos Kleijnen; Ruben G W Quek
Journal:  Int J Oncol       Date:  2019-07-16       Impact factor: 5.650

Review 5.  Involvement of DNA damage response pathways in hepatocellular carcinoma.

Authors:  Sheau-Fang Yang; Chien-Wei Chang; Ren-Jie Wei; Yow-Ling Shiue; Shen-Nien Wang; Yao-Tsung Yeh
Journal:  Biomed Res Int       Date:  2014-04-28       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.